Generic Name: colchicine
Brand Name: Myinfla
Manufacturer: Pendopharm, a division of Pharmascience Inc.
Therapeutic Area: Atherothrombotic events in coronary artery disease
Indications: Reduction of atherothrombotic events in patients with existing coronary artery disease.
Manufacturer Requested Reimbursement Criteria1: For prevention of cardiovascular events in patients after myocardial infarction and who are treated according to the national guidelines (standard of care).
Submission Type: Initial
Project Status: Pending
Call for patient/clinician input open: April 29, 2021
Call for patient/clinician input closed: June 18, 2021
Anticipated Date: May 28, 2021
Fee Schedule: Pending
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.